When a new CEO takes charge at a company, it's often because shareholders think the incumbent captain has allowed things to run off course, presenting the new leader with the immediate challenge of regaining investor confidence and getting operations back on track.
That’s the situation unfolding at German pharmaceutical giant Bayer where mutineering shareholders have pressured the board to replace longtime CEO Werner Baumann a year before his planned departure.
